Bottom line
For relief of menopausal hot flashes, night sweats, and related symptoms, hormone replacement therapy is the most effective option available. On that point medicine barely argues 1.
The argument is not "does it work." It is "what does it cost." How large the risks are for breast cancer, dementia, and cardiovascular disease is far patchier than the public picture 13.
Most clinicians accept a time window. Starting within ten years of menopause, at a younger age, has a better balance of benefit and risk. Starting many years later, the benefit shrinks and the risk may rise 1.
The 2002 preliminary report from the Women's Health Initiative (WHI) sent hormone-therapy use down by 70 to 80 percent. That report was over-read for a long time. The absolute size of the breast-cancer signal was small, and it showed up mainly in a combined regimen that is now largely retired 129.
On dementia, a case-control study of Danish national registry data found an association between hormone use and dementia. Studies of that kind cannot prove cause 310.
Whether to use it, when to start, and how long are a weighing of symptoms, family history, and preference. That weighing belongs with a clinician who knows menopause care 111.
What it is
Menopause is the process by which ovarian function comes to a stop. Estrogen and progesterone fall sharply. The classic picture is vasomotor symptoms — hot flashes and night sweats — plus loss of bone density, loss of muscle strength, and changes in mood and sexual function 1.
Hormone replacement therapy (HRT) means exogenous estrogen, plus a progestogen if the uterus is still present, to replace hormones the body no longer makes. It is not new. In the second half of the twentieth century it was a routine way to ease menopausal symptoms 12.
The turn came in 2002. The preliminary WHI results came from the estrogen-plus-progestin trial, in women with a uterus. The estrogen-alone trial was not published until 2004 912. In the combined-hormone group the coronary heart disease hazard ratio was 1.29, and breast cancer increased 9. After heavy press coverage, HRT use fell 70 to 80 percent within a few years 12.
In 2003 the U.S. Food and Drug Administration put a black-box warning on estrogen products. More than twenty years later, an expert panel convened by the agency called in public for that warning to be removed, on the ground that the evidence of that era was over-read 2.
One technical detail is worth knowing. The combined regimen of the WHI era used the synthetic progestin MPA. Clinical practice has largely moved to micronized progesterone. Booking MPA's account to every hormone therapy in use today is not a fair reading 1.
Why it matters
Menopause is not "endure a few years of hot flashes and it passes." In an interview, urologist Rachel Rubin sets post-menopausal hormone deficiency next to osteoporosis, cardiovascular disease, dementia, and repeated urinary tract infections, and she argues that medicine has neglected this area for a long time 4.
Aging research adds a frame. Epigeneticist Morgan Levine, in an interview, says "menopause is actually an epigenetic-aging-accelerated event," and women with surgical menopause show a similar acceleration 7.
WHI had a second cost: a gap in training. Rubin points out that after WHI the medical system stopped teaching hormone therapy to clinicians. What filled the gap was a set of hormone clinics outside regulation 4.
Dementia is the newer argument. A 2023 Danish study compared 5,589 women with dementia and 55,890 controls. Women who had used combined estrogen and progestogen had a 24 percent higher risk of all-cause dementia, and the association was stronger with longer use 310.
Different perspectives
Main positions
One view puts it bluntly. For relief of menopausal symptoms, hormone replacement is the most effective treatment available, and the point is not in dispute 1.
The breast-cancer account is worked in detail. The point estimate of the breast-cancer hazard ratio in the WHI combined group was 1.24, about one extra case per thousand patient-years. In women who had never used hormones before enrollment — the majority — that difference disappeared 1.
The other half points the opposite way. In the estrogen-alone group, breast-cancer incidence did not rise. It fell. At 20 years of follow-up, breast-cancer mortality was about 40 percent lower than in the placebo group 1.
The reading offered there: what tracked with breast cancer in WHI may have been the synthetic progestin MPA, not estrogen itself 1.
On bone, that account says estrogen maintains density, and the protection disappears when hormone therapy stops. Osteoporosis drugs such as bisphosphonates can also slow bone loss, but they do not restore estrogen signaling the way hormones do 1. A hypothetical comparison shows why timing matters. At the same rate of loss, a person who starts twenty years later still has thicker bone at an advanced age 1.
On the Danish dementia study, a separate analysis was written. The hormone-using cases and the controls already differed in living alone, education, income, and chronic conditions such as high blood pressure and diabetes. Statistical adjustment does not clean that up. The study cannot be read as the drug causing dementia 3.
A topic page lists women's hormone health as one part of hormone health. It says HRT manages menopausal symptoms by replacing estrogen, often with a progestogen as well, and it names breast-cancer and cardiovascular risk explicitly 5.
The deeper material comes mostly from guests. In 2024 a full episode went to obstetrician-gynecologist Mary Claire Haver on perimenopause and menopause: the biology of symptoms, effects on body composition and cardiometabolic health, effects on psychology and lifespan, and the relationship of HRT to breast cancer and the heart 6.
On the show, Haver calls nutrition, strength training, sleep, and supplements lifestyle factors, and says they can help women prepare for perimenopause and lighten symptoms 6.
The topic page also notes that testosterone in women, and its role in muscle, bone density, and mood, is often ignored, even though popular talk of women's hormones stops at estrogen and progesterone 5.
Another aggregator page collects articles, videos, and studies on estrogen 8.
The closest account is a conversation with Morgan Levine on the pace of aging. Menopause accelerates epigenetic age, and before that point women's aging books are generally better than those of men the same age 7.
The follow-up question is worth noting. Do these biological-age markers have predictive power in younger people — how many years earlier prevention has to start 7?
One way of following up is to explain the mechanism and the measurement first, and to leave the treatment tradeoff to the clinician and the person.
Where views agree and differ
Three points line up closely:
- HRT is the most effective relief of menopausal symptoms. That is not in dispute 1.
- When it starts matters. Starting early in menopause, at a younger age, is the more defensible timing 16.
- Lifestyle — strength training, nutrition, sleep — is the shared foundation of every path 6.
The split has two layers. On prevention of chronic disease, one view holds that the benefit of hormone therapy goes past symptom relief, and that the so-called risks are either weakly evidenced or too small to be clinically meaningful 1. The wording on one topic page is more neutral, and it sets breast-cancer and cardiovascular risk down side by side 5. On how to read the evidence, one analysis treats the Danish dementia study as unable to settle cause 3. That same account says the result did not change a favorable view of menopausal hormone therapy at all 3.
A third difference is coverage. The Rubin episode is about hormone health on the female side, including estrogen, progesterone, and testosterone in women 4. The episode with Haver is likewise centered on the female life course 6.
PearHealth's synthesis
What we take: symptom relief as the first use, the time-window idea, and an individualized weighing. Those three have both randomized trials and a society position statement behind them 1911.
What we hold back: WHI studied an old formulation that is now largely retired 19. Today's mainstream pattern, transdermal estrogen plus micronized progesterone, does not yet have a randomized trial of the same grade 1. WHI's own stratified analyses show that results depend heavily on when treatment starts, so carrying the overall conclusion over to women who have just reached menopause is not appropriate 1. The dementia signal is observational. Cause is not settled 310.
Two points we want to stress. First, this is not a courage test about "daring to use hormones." It is arithmetic that puts symptom severity, family history of breast cancer, history of clots, and personal preference on the table 111. Second, watch both extremes. One is the old panic that "hormones are harmful." The other is the unregulated hormone clinic. On the show, Rubin warns that clinics of that kind take advantage of women who are short on medical care 4.
We do not sell any hormone product, and we do not think a product is required to come through menopause well.
How strong is the evidence
Randomized trials are the firmest layer, and they answer only the question they asked. The WHI combined trial enrolled 16,608 women aged 50 to 79, past menopause, with a uterus. Over a mean 5.2 years, the coronary hazard ratio was 1.29, breast cancer increased, hip fracture decreased, and total mortality did not change 9. It does not answer what happens to a woman who has just reached menopause and uses a newer formulation 1.
A case-control study can raise a question. It cannot settle cause. The Danish dementia study used national prescription and diagnosis registries. The sample is huge and the follow-up is real, but people who use hormones and people who do not already differ, and statistical adjustment does not clean that up 310.
Mechanism studies explain pathways. They do not hand out risk numbers. Estrogen maintains bone density and affects vessel function. Those pathways are clear. A clear pathway is not the same as benefit exceeding risk 1.
A society statement is a combined judgment. The North American Menopause Society's 2022 position statement kept the basic frame of early-menopause use and individualization. It sorts the evidence by strength, which is more reliable than any single news item 11.
An expert's personal experience has value and it has bias. Clinic experience cannot replace a randomized trial. That layer is worth keeping in mind when reading views of this kind.
What you can do
Questions worth raising with a clinician can follow this list:
- How severe are my symptoms — hot flashes, night sweats, sleep, mood, joint discomfort — and is medication warranted?
- Which way do family history of breast cancer, history of clots, and the state of the uterus push the balance 11?
- Is starting now still inside the time window 1?
- If medication is used, transdermal or oral, and is a progestogen needed? What are the tradeoffs 4?
- After starting, how often is a review, and what would trigger a new look?
Directions many people take:
- A few months of notes on menstrual change and symptoms are far more useful at a visit than "I don't feel well."
- Whether hormones are used or not, strength training, protein, and sleep are the foundation 6.
- People who care about bone can consider one bone-density measurement as a later comparison 1.
- For someone already on therapy, stopping is the same kind of decision as starting. It is worth making with a clinician, not by stopping on one's own.
- Marketing for "bioidentical hormones" online is worth reading against Rubin's warning about unregulated hormone clinics 4.
Common misconceptions
Misconception one: hormone therapy generally raises breast-cancer risk. The WHI signal appeared only in the combined group, at about one extra case per thousand patient-years. In the estrogen-alone group, both incidence and mortality went down, not up 1.
Misconception two: WHI settled it, and HRT was shown to be harmful. The trial's participants were older on average and long past menopause, and the formulation was the old one. Carrying that conclusion over to women who have just reached menopause is something even the trial's own leaders oppose 12.
Misconception three: menopause is a natural process, so enduring it is enough. Beyond symptoms there is a long account in bone density and cardiometabolic health. Treating or not treating is a legitimate choice that puts quality of life on the scale 46.
Misconception four: one tube of blood decides whether hormones are warranted. Rubin's episode has a section specifically on not being misled by hormone labs 4. Haver also says she rarely orders hormone-level labs, because they help little, and instead checks thyroid, autoimmunity, and nutrient shortfalls, so that every symptom is not booked to perimenopause 6.
Misconception five: a black-box warning still in place means the drug is unsafe. The warning was an administrative decision in 2003 based on the evidence then. In 2025 an expert panel called in public for removal. The discussion is still open 2.
How it connects to your blood work
No blood test can decide for you whether to use hormone therapy. The markers below are closely tied to this stage, and they are worth reading together.
- Estradiol (estradiol): the main estrogen the ovary makes. It falls markedly around menopause and is one reference for the stage.
- Follicle-stimulating hormone (fsh): rises as ovarian function declines, and is often read with estradiol to support the picture of menopause.
- Sex hormone-binding globulin (shbg-female): the carrier that transports sex hormones in blood. Its level affects how much hormone is free.
- Total testosterone, women (testosterone-total-female) and free testosterone, women (testosterone-free-female): testosterone in women has been ignored for a long time. It relates to muscle, bone density, and mood 5.
- DHEA sulfate (dhea-s-female): a hormone precursor from the adrenal gland. Rubin is talking about local vaginal DHEA, not about using this blood test to decide on medication 4.
- TSH (tsh) and free T4 (free_t4): Haver says she orders thyroid-related checks so that other problems are not missed and every symptom is not booked to perimenopause. The two are worth reading together 6.
- 25-hydroxyvitamin D (vitamin-d-25oh): a fat-soluble vitamin that takes part in bone metabolism, worth reading next to bone density.
The meaning of these numbers depends on stage and symptoms. A single number is not a reason to start or stop medication.